Literature DB >> 3469197

The in-vivo postantibiotic effect of imipenem and other new antimicrobials.

S Gudmundsson, B Vogelman, W A Craig.   

Abstract

The postantibiotic effect (PAE) in vivo of imipenem, cefoperazone and latamoxef was investigated in a neutropenic mouse thigh model. Two hours after inoculation of 10(6) cfu of Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa into each thigh, the neutropenic mice were treated with single doses of 50-200 mg/kg imipenem, 40-1200 mg/kg cefoperazone and 50-100 mg/kg latamoxef. Serum levels exceeded the MIC for 1.1-2.9 h. Cefoperazone and latamoxef induced PAEs of 2.1-5.6 h for S aureus, but no significant PAEs were induced for the Gram-negative bacilli. In contrast imipenem produced PAE of 0.9-4.6 h with P. aeruginosa. However, strain variation was observed in the duration of the PAE after imipenem. These data are in concordance with the PAEs of the antimicrobials under study when these are determined in vitro. The implications of these findings for clinical use of these drugs need further evaluation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3469197     DOI: 10.1093/jac/18.supplement_e.67

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  28 in total

1.  Postantibiotic leukocyte enhancement of meropenem against gram-positive and gram-negative strains.

Authors:  A Novelli; S Fallani; M I Cassetta; S Conti; T Mazzei
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

Review 2.  Continuous infusion of beta-lactam antibiotics.

Authors:  W A Craig; S C Ebert
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 3.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

4.  A Human Biofilm-Disrupting Monoclonal Antibody Potentiates Antibiotic Efficacy in Rodent Models of both Staphylococcus aureus and Acinetobacter baumannii Infections.

Authors:  Yan Q Xiong; Angeles Estellés; L Li; W Abdelhady; R Gonzales; Arnold S Bayer; Edgar Tenorio; Anton Leighton; Stefan Ryser; Lawrence M Kauvar
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

5.  Variation in postantibiotic effect of clindamycin against clinical isolates of Staphylococcus aureus and implications for dosing of patients with osteomyelitis.

Authors:  I B Xue; P G Davey; G Phillips
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

6.  Postantibiotic and bactericidal effect of imipenem against Pseudomonas aeruginosa.

Authors:  I Odenholt; B Isaksson; L Nilsson; O Cars
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-02       Impact factor: 3.267

7.  Postantibiotic effects of imipenem, norfloxacin, and amikacin in vitro and in vivo.

Authors:  J Renneberg; M Walder
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

8.  Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa.

Authors:  R White; L Friedrich; D Burgess; D Warkentin; J Bosso
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

9.  Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD).

Authors:  M C Vos; H H Vincent; E P Yzerman
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

10.  Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model.

Authors:  B Fantin; J Leggett; S Ebert; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.